As TRIM24-AR signature genes are equally activated in TRIM28-high tumors as in SPOP-mutant PCa, TRIM28 expression, easily monitored at mRNA level, could be used to select CRPC patients that might not have SPOP mutation for TRIM24-targeted therapeutics that was previously proposed19. The gene discussed is TRIM24; the disease is posterior cortical atrophy.